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ABSTRACT 
Proteins and peptides have the wide range of therapeutic agents emerged within and the administration is through needle and syringe i.e., 
parenteral delivery is the choice of route of administration, but it has drawn some drawback related to patient incompliance such as causing 
pain during administration, sterility and cost of the product though the bioavailability is 100%. The route of administration  plays an important 
role as it have an impact on the therapeutic outcome of the drug, with the advancement in the branch of pharmaceutical biotechnology. Based 
on the biophysical and biochemical properties a delivery system was designed for protein and peptide based therapeutic and cl inical 
application have come into existence through non-invasive delivery and in addition, this dosage form can be significantly self-administered by 
patients, manufacturing cost would be less compared to the injections. The main aim is to focus in this review article is the recent advances in 
the delivery of therapeutic proteins and peptides via different non-invasive routes and the barriers affecting the drug transportation, 
approaches, advantages, challenges. 
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INTRODUCTION 
Proteins are the bio-polymers of amino acids, joined by 
peptide bonds. The amino acid sequence which is encoded 
by its gene determines a protein’s structure and function. 
Proteins and peptides can be distinguished by the presence 
of number of amino acids. Proteins contain 50 and more 
amino acids whereas peptides contain less than 50 amino 
acids. The molecular weight greater than 10,000 are referred 
to as proteins and those which less than 10,000 are referred 
to as peptides.[1] Proteins have secondary and tertiary 
structures and their molecular size is greater than 
pharmaceuticals which leads to physical and chemical 
degradation. Proteins and peptides are very important in 
biological cells and lack of them causes diseases like diabetes 
mellitus, due to lack of protein called insulin. Hence, the US 
Food and Drug Administration in 1982, found the 
recombinant insulin and it became commercially available 
for patients suffering with diabetes mellitus.[2] 
Many naturally occurring proteins and peptides were 
identified, and these often have vital roles in human 
physiology. All naturally occurring ones are not directly 
suitable for the therapeutic use, because they have intrinsic 
weakness, poor chemical and physical stability, short plasma 
half-life. These weaknesses have been successfully resolved 
through SWOT analysis. It is described below in the figure 
no.01. [ 3,4] 
 
 
Santosh Kumar et al                                                                                        Journal of Drug Delivery & Therapeutics. 2019; 9(4-A):815-819 
ISSN: 2250-1177                                                                                  [816]                                                                                 CODEN (USA): JDDTAO 
 
Fig no.01, SWOT analysis description 
Prerequisite of Protein and Peptide Drug Delivery 
System [5-7] 
 These are important in biological cells and organic 
molecules. 
 Lack of these may be cause diseases like diabetes 
mellitus, which is caused due to lack of insulin protein. 
 For the protein and peptide-based pharmaceuticals, 
hybridoma, r-DNA technologies are used. 
Advantages of Protein and Peptide Drug Delivery 
System [8-14] 
 Bradykinin, increases the peripheral circulation. 
 Erythropoietin, used for production of RBC. 
 Gonadotropin, induces ovulation. 
 Insulin, maintains blood sugar level. 
 Oxytocin, used in management of labour pain. 
 Protein tissue, plasminogen, activator used for heart 
attack, stroke etc. 
 Somatostatin, decreases bleeding in gastric ulcer. 
Pharmaceutical Approaches [15-24] 
The pharmaceutical approaches for protein and peptides are 
as follows, 
I. Chemical modifications 
II. Enzyme inhibitors 
III. Penetration enhancers 
IV. Formulation vehicle 
V. Mucoadhesive polymeric system 
Chemical modification  
Proteins and peptides are modified chemically which plays 
an important role, in order to improve the enzymatic 
stability and membrane permeations. This type of 
modification can be applied to reduce immunogenicity.  
Enzyme inhibitors 
This modification is an enzymatic approach of protein and 
peptide drug delivery systems. Gastro-intestinal tract and 
liver involve in metabolization of protein and peptides into 
smaller fragments of amino acids. 
Penetration enhancers: 
These are most important components of protein and 
peptides, during formulation these are responsible for the 
disruption of the mucosal barriers and hence improve 
penetration of larger macromolecular substances. 
Formulation vehicles: 
The protein and peptide delivery systems can be 
administered through oral route successfully by the use of 
various carrier systems like; 
1. Dry Emulsion  
2. Microspheres  
3. Liposomes  
4. Nanoparticles 
Mucoadhesive polymeric systems 
These systems are important as they prevent the problem 
associated in pre-systemic metabolism at the site of action 
and also increases or decreases the drug clearance rate. 
For the effective delivery system, the physiochemical and 
biological properties like molecular size, conformational 
stability, biological half-life, immunogenicity, sensitivity to 
heat and light, dose, chances of breakdown in both physical 
and biological environments, mechanism of transport etc., 
plays an important role as well as considered. [24] These can 
be delivered through parenteral route but led to an 
disadvantage as it is causing pain during delivery, cost of the 
product etc. The route of administration has an impact on 
therapeutic outcome of drug, recent advances in 
pharmaceutical biotechnology have made a specific route of 
delivery as well as delivery system which added importance 
in delivery of proteins and peptides, like transdermal, 
pulmonary routes, ophthalmic, buccal, rectal, intra-uterine, 
vaginal. [25,26] 
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Various routes of administration for protein and 
peptide drugs 
The various routes of administration for proteins and 
peptide drugs are; 
 Parenteral delivery system 
 Non-parenteral delivery system 
1. Oral route 
2. Nasal route 
3. Buccal route 
4. Ocular route 
5. Transdermal route 
6. Pulmonary route 
7. Rectal route 
 Parenteral delivery system 
The parenteral delivery system includes intravenous, 
intramuscular, subcutaneous, intraperitoneal and 
intrathecal. It used to be the major route of choice for 
administering the protein and peptides but due to high cost, 
pain during administration new delivery systems came into 
existence for better patient compliance. [27] 
 Non parenteral delivery systems 
1. Oral route, Oral route is better route over any other route 
because of good patient compliance and acceptance. 
Preparing and formulating protein and peptide drug delivery 
system for the gastrointestinal (GI) route is difficult because 
of its unfavourable conditions such as pre-systemic enzymatic 
degradation and poor membrane permeability. 
 Barriers for oral absorption: Intestinal epithelial tight 
junctions in the body prevent the entry of peptides and 
proteins into the systemic circulation. The major 
disadvantage in oral route is denaturation of proteins 
due to acidic environment in stomach, degradation of 
proteins in stomach and intestine due to proteolytic 
enzymes, intestinal wall which is impermeable to 
macromolecules, mucin barrier which is formed by 
mucus that is secreted by goblet cells, and intestinal 
transit time. 
 Enzymatic barriers: When proteins are in intact form, 
they are not absorbed in humans in most of the cases. 
They get break down into amino acids or di- and tri-
peptides first in the GI tract (GIT).  Trypsin, 
chymotrypsin, carboxypeptidase, elastase, which are 
secreted from pancreas convert proteins, and 
polypeptides to oligopeptides. In small intestine when 
compared with the total degradation the luminal 
degradation is only up to 20%.  After the entry of 
oligopeptides into the cell the rest of the degradation 
takes place by converting them into amino acids (up to 
70%) and di- and tri- peptides (up to 30%) To improve 
oral absorption of protein and peptide drugs from the 
GIT, the above-mentioned barriers must be avoided. This 
may be possible to achieve to some extent using enzyme 
inhibitors or by chemical modification. 
 Bioavailability: Captopril, Lisinopril, and enalapril have 
good oral bioavailability due to their low-molecular 
weight and their ability to inhibit tissue carboxyl 
peptidases. Cyclosporine is a cyclic peptide with a 
number of methylated amino acid residues and is 
resistant to hydrolysis and therefore has good 
bioavailability. Some protease inhibitors and absorption 
enhancers have been co-administered with peptide drugs 
to enhance their oral absorption. A good example is oral 
arginine-vasopressin. To produce a 50% reduction in 
urine flow, in the rat, an oral dose of about 3500/mol was 
required. When the drug was co-administered with 
aprotinin, a protease inhibitor, the oral dose was reduced 
to 1000/mol. 
2. Nasal route: It is a chief route for protein and peptide 
drug delivery next to the parenteral route for achieving 
systemic effect. Generally suitable for highly potent 
protein/peptide with low molecular weight. 
 Barriers for nasal absorption: This route has more 
advantages like larger surface area for absorption. The 
lipophilicity of the molecule plays major role in 
absorption. By this route even the central nervous 
system can be targeted by having improved delivery rate. 
Vaccines are also delivered by this route. 
 Nasal mucosa and nasal epithelium: Epithelium of 
nasal is loosely packed with high permeability and 
vasculature. This route delivers drugs by transport 
mechanisms like passive diffusion, carrier-mediated 
transport, and transcytosis.  Compounds such as 
desmopressin, insulin, and human growth hormones 
have low absorption rate because of their molecular 
weight. Drugs by this route permeate at a faster rate 
when they have a low molecular weight.  
 Muco-ciliary clearance: Nasal muco-ciliary clearance 
(NMC) plays a crucial role in delivering the drugs by this 
route. NMC has a natural defence mechanism in which 
can help in eliminating the foreign objects and improving 
the absorption of drug molecules. Antihistaminic drugs, 
beta blockers, general anaesthetics, cocaine, etc., arrest 
the muco-ciliary clearance.  
 Drug metabolism: Even though nasal route provides 
low metabolic environment, metabolism of proteins and 
peptide molecules in nasal cavity is a major barrier for 
bioavailability. The main enzymatic barrier present in the 
nasal mucosa is cytochrome P450 enzymes. It is present 
in both respiratory and olfactory mucosa, thus reducing 
both nose-to-blood and nose-to-brain transport of drugs. 
Low bioavailability of protein and peptide drugs is 
obvious by the presence of various proteolytic enzymes 
such as exopeptidase (mono and diamino peptidase) and 
endopeptidase (serine, cysteine, and aspartic peptidase) 
3. Buccal route: Buccal membrane has numerous elastic 
fibres in the dermis, which is another barrier for diffusion of 
drug across the buccal membrane.  
 The barriers for efficient drug absorption are  
 Mucus layer covering the oral epithelium.  
 Epithelial barriers.  
Peptidases in the saliva and the mucus layer and microbial 
flora. The buccal peptide absorption is assumed to be via 
passive absorption mechanism. The various parameters that 
influence the extent of buccal peptide absorption are 
molecular weight, polarity, conformation, dissociation and 
enzymatic and chemical stability. 
4. Ocular route: Ocular route of delivery is useful in treating 
of ocular inflammation, corneal wounds, and glaucoma. The 
administration of biopharmaceuticals through eye is difficult 
because of its normal processes like blinking, tearing, and 
drainage from the eye which washes out the drugs when 
administered. 
 Drug absorption: Cornea consists of three layers, Two 
boundary cellular layers, the epithelium, the 
endothelium, and the stroma (a thick connective tissue) 
in between. The corneal epithelium is a non-keratinized 
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stratified squamous epithelium, 5-6 cell layers in 
thickness. A drug when administered topically on the 
precorneal area comes into contact with the corneal 
and conjunctival epithelia followed by absorption by 
ocular tissue. Then, it enters into the systemic 
circulation by various processes like corneal 
absorption. Conjunctiva is highly perfused and most of 
the absorbed drug enters to the systemic circulation. 
The nasolacrimal secretion also another process 
through which drug is lost. The enzymes such as 
neutral protease and aminopeptidase also cause 
destruction of proteins and peptides. Some novel 
approaches such as cyclodextrin complexes of 
cyclosporin have increased the bioavailability through 
corneal tissues. 
5.Transdermal route: Transdermal route has a lot of 
advantages because of its larger surface area which helps in 
improving the permeability of the drugs with the use of 
appropriate enhancers. The stratum corneum (SC) is the 
major barrier which avoids first-pass metabolism. This 
route has high patient compliance and at any time the drug 
action can be terminated. 
 Barrier for transdermal delivery: SC is the outer 
most layer which acts as a major layer for permeation. 
Drugs through skin permeate by passive diffusion. The 
ideal log P, molecular weight, melting point, solubility, 
and dose of the drug influences the permeation through 
skin. Chemical permeation enhancers play major role 
as passive enhancement of drugs through skin. 
 Skin barrier function: The major barrier of skin is SC, 
which is the thin, outermost layer of the epidermis. The 
SC consists of several layers of protein-filled 
corneocytes (i.e., terminally differentiated 
keratinocytes) embedded in an extracellular lipid 
matrix. Passive permeation across the SC is believed to 
occur primarily through the intercellular lipid pathway 
which constitutes the only continuous phase through 
the SC, appendageal transport through hair follicles, 
and sweat glands is another potential route, these 
structures offering “shunt” pathways across the 
continuity of the SC. Visualization of appendageal 
transport has been accomplished both for passive 
diffusion and for percutaneous transport enhanced by 
one means or another (e.g., iontophoresis). A third 
possible route across the SC is the transcellular path. 
 Approaches for transdermal delivery, Several 
approaches have been explained which provides 
additional driving force in the form of electrical 
(iontophoresis) or ultrasound (sonophoresis) energies, 
structural perturbation of SC, penetration enhancers, or 
a combination of these strategies. 
 Iontophoresis, To a few square centimetres of skin, a 
small amount of physiologically accepted current is 
applied to drive drug molecules into and across the 
skin. Iontophoretic delivery is achieved by 2 ways of 
electro-repulsion and electroosmosis  
 Electro-repulsion, Delivery of charged molecule 
across the skin is possible due to repulsion between 
same charges, when a charged molecule is placed under 
an electrode of same polarity. 
 Electroosmosis, Skin is negatively charged; transport 
of positively charged drugs is possible. Under the 
influence of electric current, net flow of water from 
anode to cathode occurs which is called electroosmosis.  
6. Pulmonary route: Particles that reach the alveoli can be 
absorbed into the systemic circulation, avoiding first pass 
metabolism and the harsh conditions of the gut. The lung is, 
by necessity, a durable organ. An average person daily 
inhales air along with all the dust and all the particles 
floating in it. The safety issue pertaining to the pulmonary 
route for peptide/protein administration should be 
considered with regard to immunogenicity of peptide 
release. Most of the peptide/protein drugs require 
absorption enhancers to attain a reasonable level of 
absorption. 
7. Rectal route, Rectal delivery of peptide and protein drugs 
is another very active area of research. 
 Barriers for rectal absorption, The barriers of drug 
absorption are apical membrane, cell body, and tight 
junctions. The enzymatic barrier includes the presence 
of peptidases. 
 Approaches for rectal delivery,  
 Absorption enhancers play a major role in improving 
rectal absorption. The absorption enhancers, increases 
the membrane fluidity, increases the size of the 
intercellular space, and enhances the solubility of 
mucosal membrane thereby increasing the water 
penetration. This also reduced the viscosity of mucus 
layer. The various absorption enhancers include 
sodiumtaurodihydrofusidate, sodium 5-methoxy 
salicylate, enamine derivatives, and sodium caprate. 
Some of the protease inhibitors are also can be used as 
enzyme inhibitors, which includes aprotinin, trypsin 
inhibitors, bacitracin, puromycin, bestatin, and bile 
salts. 
 Drug absorption, Although extensive villi and 
microvilli are not present in the rectum tissue, 
sufficient surface area is present to allow absorption of 
readily permeable drugs. There is an extensive motility 
small intestine in contrast to rectum enables high 
concentration gradient. Together with a limited fluid 
volume in the lower colon, typically 2-3 ml of inert 
mucous fluid in the absence of faecal material, the static 
environment of the rectum and lower colon provides 
an area for maintaining significantly higher drug 
concentrations than is readily achievable in the small 
intestine. Significant rectal absorptions of growth 
hormone have also been demonstrated with the help of 
absorption enhancing agents. The apical membranes of 
the small intestine epithelial cell layer express high 
levels of membrane-associated or membrane-bound 
enzymes, such as peptidases and saccharides, which 
are not present in high amounts on the apical surfaces 
of epithelial cells in the rectal cavity. 
8. Vaginal delivery: Vaginal administration of peptide 
and protein drugs which are used specifically for the 
treatment of female-related conditions is a favourable 
alternative to parenteral administration. 
 Vaginal barrier for absorption: The vaginal wall consists of 
three main layers, An outer fibrous layer, a middle muscular 
layer, and an epithelial layer. The vaginal epithelium is a 
stratified, squamous epithelium which rests on a lamina 
propria. The surface area of the vagina is increased by 
numerous folds in the epithelium and by micro-ridges 
covering the epithelial cell surface. In common with other 
mucosal routes, drugs administered vaginally will be 
transported across the vaginal membrane by a number of 
different mechanisms  
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i. By diffusion through the cell due to a concentration 
gradient (transcellular route); 
ii. By a vesicular or receptor-mediated transport mechanism; 
or 
iii. By diffusion between the cells through the tight junctions 
(intercellular route). 
 Approaches for vaginal administration 
1. Hydrogel slabs, The vaginal slabs are produced from 
polyethylene glycol -hexane tri-oldiisocyanate hydrogel and 
form a tri-dimensional lattice which swells when exposed to 
water and in this way it can be loaded with drug. After 
drying, the drug is trapped in the hydrogel matrix in a near 
dry state which results in increased stability of the drug. The 
hydrogel swells and the drug is released, after vaginal 
administration. 
2. Microbicidal gel, Microbicidal gel containing monoclonal 
human antibodies is used for topical immunization, for 
protecting genital skin, and epithelia from HIV and STIs 
pathogens. 
3. Mucoadhesive delivery systems, Polycarbophil, 
hydroxypropyl cellulose, and polyacrylic acid are the bio-
adhesive polymers employed for intravaginal formulations. 
Hyaluronic acid-based intravaginal delivery of calcitonin, a 
polypeptide used in the treatment of post-menopausal 
osteoporosis, has shown promise for intravaginal 
administration of drugs for systemic effect. 
CONCLUSION 
 According to recent studies proteins and peptides are 
gaining a wide range of awareness in drug delivery. Through 
parental route delivering protein and peptide drugs contains 
a lot of disadvantages like patient incompliance.  Non-
invasive drug delivery is gaining importance. A lot of 
intricacies involved in understanding the non-invasive 
delivery routes, scientists have started devising a novel 
technology to administer these drugs with improved 
bioavailability. Because of the limitation of the current non-
invasive route of protein and peptide drug delivery system 
but the continued research may help to enable the cost-
effective, useful, and patient compliant biopharmaceuticals. 
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